A Meta-Analysis of HIF-1and Esophageal Squamous Cell Carcinoma (ESCC) Risk

详细信息    查看全文

• 作者：Guogui Sun (1)
  Wanning Hu (1)
  Yifang Lu (2)
  Yadi Wang (3)
  
• 关键词：ESCC ; HIF ; 1 Meta ; analysis ; Survival
• 刊名：Pathology & Oncology Research
• 出版年：2013
• 出版时间：October 2013
• 年：2013
• 卷：19
• 期：4
• 页码：685-693
• 全文大小：
• 作者单位：Guogui Sun (1)
  Wanning Hu (1)
  Yifang Lu (2)
  Yadi Wang (3)
  
  1. Department of Chemoradiology, People Hospital Affiliated to Hebei United University, Tangshan, 063000,, Hebei Province, China
  2. Department of Endocrinology (Section I), Tangshan Workers Hospital, China, Tangshan, 063000,, Hebei Province, China
  3. Department of Radiotherapy, The Military General Hospital of Beijing PLA, Beijing, 100700, China
  
• ISSN：1532-2807

文摘

To investigate the correlation of hypoxia-inducible factor-1(HIF-1 expression with clinical prognosis and efficacy of radiochemotherapy in esophageal squamous cell carcinoma (ESCC). Studies assessing the clinical or prognostic significance of HIF-1expression in ESCC published prior to December 2011 were selected by searching PubMed, EMBASE, Cochrane Library, and (China National Knowledge Infrastructure) CNKI. A meta-analysis was performed to clarify the impact of HIF-1expression on clinicopathological parameters or survival in ESCC. A total of 16 studies met the inclusion criteria, which included 1261 patients with ESCC. Accordingly, the level of HIF-1expression in esophageal tissues of patients with ESCC was significantly higher than that in normal patients (odds ratio, OR=33.111, 95% confidence interval, CI=11.9122.040). The expression of HIF-1correlated with the depth of invasion (OR=1.701, 95% CI=1.076.705), clinical TNM stage (OR=2.160, 95%CI=1.516.077), as well as lymph node metastasis (OR=2.393, 95% CI=1.319.344), regardless of differentiation grading (OR=1.185, 95% CI=0.859.635). Furthermore, there was a significant association of increased HIF-1expression with poorer radiochemotherapy outcomes, 2-year overall survival (OR=0.219, 95% CI=0.104.461) and survival (OR=0.320, 95% CI=0.115.887, P<0.05) in patients with ESCC. In addition, HIF-1expression correlated with VEGF expression in the ESCCs (OR=4.635, 95%CI=2.591.292). Increased expression of HIF-1plays an important role in the malignant biology of ESCC resulting in significantly poorer radiochemotherapy outcomes and 2-year overall survival. HIF-1expression may be a prognostic factor, as well as a potential target for therapy in patients with ESCC.